Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

A Review Of The Use Of Trastuzumab (Herceptin) Plus Vinorelbine In Metastatic Breast Cancer.

A. Chan
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The combination of trastuzumab (Herceptin) and vinorelbine (Navelbine) in the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) is valuable for several reasons. There is proven synergism of these agents in preclinical models, both agents are well tolerated and there is minimal overlapping toxicity. This article reviews clinical experience with trastuzumab and vinorelbine from phase II/III trials including >450 assessable patients. Results across the trials show objective response rates for the combination in the range of 44%-86% (51%-86% as first-line treatment) and a median duration of response of 10-17.5 months. Approximately 50% of patients experience grade 3/4 neutropenia, which is of short duration and manageable. Symptomatic cardiac events are infrequent (seven episodes of grade 3 toxicity across all trials). Overall, trastuzumab-vinorelbine combination therapy offers patients with HER2-positive MBC, an effective and well-tolerated treatment that is suitable for prolonged duration of use.
This paper references
Vinorelbine and trastuzumab as first line therapy in patients with HER2-positive metastatic breast cancer — interim analysis of a prospective, open-label, multicentre phase II trial
M de Wit (2004)
10.1200/jco.2006.24.18_suppl.650
Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study.
H. Burstein (2006)
10.1007/s00280-005-0092-6
Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial
R. Bartsch (2005)
10.1200/JCO.2004.01.120
Clinical cardiac tolerability of trastuzumab.
E. Perez (2004)
10.1200/JCO.2005.23.16_SUPPL.868
A multicenter study of trastuzumab (H) and vinorelbine (N) as first and second line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC)
R. Franquesa (2005)
10.1200/JCO.2006.05.7802
Myths and facts on adjuvant carboplatin for stage I seminoma.
J. Aparicio (2006)
A single-centre phase 2 study of vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer
E De Maio (2004)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1200/JCO.2004.22.14_SUPPL.731
Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cance.
G. Bernardo (2004)
10.1016/J.EJCA.2004.01.011
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Shen Kun-wei (2008)
10.1200/JCO.2001.19.10.2722
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
H. Burstein (2001)
10.1200/jco.2004.22.14_suppl.643
First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial.
D. Yardley (2004)
10.1038/sj.bjc.6603351
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
A. Chan (2006)
Phase I trial of Herceptin and Navelbine for patients with HER-2/neu (+) advanced breast cancer
PA Kaufman (2002)
10.1053/J.SEMINONCOL.2004.07.020
Maximizing clinical benefit with trastuzumab.
R. Bell (2004)
10.1093/JNCI/DJH131
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
M. Pegram (2004)
Interim analysis of a phase II study of biochemotherapy in metastatic breast cancer (MBC)
A Lal (2005)
10.1200/JCO.2001.19.6.1865
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
R. Bast (2001)
10.1093/ANNONC/MDI326
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A. Goldhirsch (2005)
10.1634/THEONCOLOGIST.7-5-410
Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.
M. Jahanzeb (2002)
10.1200/JCO.2003.02.018
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
H. Burstein (2003)
10.1093/ANNONC/MDJ110
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
P. Papaldo (2006)
10.1124/pr.56.2.6
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
G. Minotti (2004)
10.1200/JCO.2004.22.14_SUPPL.831
Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC).
M. de Wit (2004)
10.1159/000055397
Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials
J. Baselga (2001)
10.1200/JCO.2006.24.18_SUPPL.10607
Optimal tolerance of an all-oral combination chemotherapy (CT) of oral vinorelbine (NVBo), capecitabine (C) with/without trastuzumab (T) in metastatic breast cancer (MBC) patients (pts): Safety Results of two international multicenter studies.
A. Chan (2006)
10.1200/JCO.2005.23.16_SUPPL.591
Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support
M. Jahanzeb (2005)
10.1200/JCO.2005.04.173
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
A multicenter study with trastuzumab and vinorelbine as first and 2nd line treatment in patients (pats) with Her2 positive metastatic breast cancer (MBC)
JL Bayo-Calero (2004)
10.1097/01.MP.0000052102.90815.82
Current Perspectives on HER2 Testing: A Review of National Testing Guidelines
M. Bilous (2003)
10.1054/bjoc.2000.1203
Vinorelbine – a clinical review
R. Gregory (2000)



This paper is referenced by
10.1179/joc.2011.23.1.32
Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
C. Ferrario (2011)
10.1007/978-2-8178-0076-9_21
Stratégies thérapeutiques des cancers métastatiques RH+, HER2+ : trastuzumab, chimiothérapie, hormonothérapie
B. Coudert (2010)
10.1016/j.ctrv.2009.04.002
Management of primary and advanced breast cancer in older unfit patients (medical treatment).
M. Aapro (2009)
10.4143/crt.2008.40.2.81
Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.
H. Kim (2008)
10.1002/9780470660379.CH5
Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings
J. Carver (2010)
10.1016/j.breast.2009.12.011
Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer.
M. Iorfida (2010)
10.1177/030089160909500625
Inhibition of HER2/estrogen Receptor Cross-Talk, Probable Relation to Prolonged Remission of Stage IV Breast Cancer: A Case Report
G. Tisman (2009)
10.1093/annonc/mds284
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
A. Awada (2013)
Cardiotoxicity of Non-Cardiovascular Drugs
G. Minotti (2010)
10.1371/journal.pone.0052940
Synthesized Multiple Antigenic Polypeptide Vaccine Based on B-Cell Epitopes of Human Heparanase Could Elicit a Potent Antimetastatic Effect on Human Hepatocellular Carcinoma In Vivo
J. Zhang (2013)
10.1007/978-2-8178-0076-9_34
Modifications de la prise en charge des traitements systémiques (hormonothérapie, chimiothérapie, traitements ciblés) dus à l’âge
J.-P. Spano (2010)
10.3816/CBC.2009.n.004
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
J. Infante (2009)
10.1016/j.biomaterials.2010.08.053
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery.
Y. Liu (2010)
10.1007/s00204-014-1246-2
Canonical and new generation anticancer drugs also target energy metabolism
S. Rodríguez-Enríquez (2014)
The efficacy of HER 2-targeted agents in metastatic breast cancer : a meta-analysis
C. A. Harris (2011)
10.1093/annonc/mds285
Breast cancer management and outcome according to surgeon's affiliation: a population-based comparison adjusted for patient's selection bias.
F. Taban (2013)
10.1007/s12609-012-0096-2
New Vinca Alkaloids in Clinical Development
P. Fumoleau (2012)
10.1517/14656566.9.16.2901
Vinorelbine in breast cancer
J. Bonneterre (2008)
10.1007/978-2-8178-0245-9_33
Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs
S. Guiu (2012)
10.7314/APJCP.2013.14.12.7111
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Zhen-Li Zhu (2013)
10.3109/07357907.2010.496755
A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer
D. Yardley (2010)
10.1038/s41416-018-0194-7
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
A. D. de Langen (2018)
10.1093/annonc/mdq593
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
C. Harris (2011)
10.1634/THEONCOLOGIST.12-11-1288
First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment.
A. Morabito (2007)
10.1186/1471-2407-7-50
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial
E. De Maio (2006)
10.1016/j.breast.2010.11.008
Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.
S. Goel (2011)
10.1038/s41598-019-48212-2
HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
Altuna Halilovic (2019)
10.1186/1471-2407-10-28
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
S. Redana (2009)
10.1111/tbj.12071
A Systematic Review of Vinorelbine for the Treatment of Breast Cancer
Y. Xu (2013)
10.1155/2012/198412
Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series
V. Di Lauro (2012)
10.4048/jbc.2011.14.2.140
Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
Y. R. Lee (2011)
10.1186/1471-2407-8-209
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
F. Montemurro (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar